Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 03 August 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) is looking to help fund the development of products intended to treat orphan diseases in areas where no treatments currently exist or the existing treatments are inferior.
In a Federal Register post on 3 August, FDA noted the grant money will total $14.1 million, with $4.1 million going toward the development of between five and 10 new awards during the first year and the remaining $10 million supporting continuation awards thereafter.
The grants, administered by FDA's Office of Orphan Product Development (OPD), will be used to support clinical studies on safety or effectiveness that will, "Either result in, or substantially contribute to, market approval of these products."
Phase 1 studies will be eligible for grants of up to $200,000 per year for three years, while Phase 2 and 3 studies may receive up to $400,000 per year for four years. Continued funding beyond the first year will be contingent upon performance factors, compliance with regulations and the availability of continued funding-far from certain with impending budget cuts set to come into effect in January 2013.
All entities-public, private, academic, government, for-profit and nonprofit-will be allowed to apply for the grants, though for-profit entities will be required to exclude profit margins in their request. Further, any entity that uses funds to lobby the government will be disqualified from receiving an award, likely eliminating many larger companies.
Orphan diseases are defined as any condition affecting fewer than 200,000 people in the US. Many diseases have few treatments available to those suffering from the condition, and those without any treatments at all are referred to as "neglected" orphan diseases.
Under the Orphan Drug Act, orphan diseases are eligible for special incentives meant to make the development of treatments financially palatable to pharmaceutical manufacturers and investors, many of whom once shied away from developing drugs due to the low financial returns or possible losses. Under the Act, sponsors may receive financial incentives, expedited reviews for approval and additional years of marketing exclusivity.
Read more:
Tags: Orphan Devices, Grants, HDE, Orphan Diseases, Latest News, Orphan Drugs
Regulatory Focus newsletters
All the biggest regulatory news and happenings.